
EDSA Stock Forecast & Price Target
EDSA Analyst Ratings
Bulls say
Edesa Biotech Inc. has demonstrated promising results from its Phase 2b trial of EB01, which showed significant improvements in skin health among 200 patients with allergic contact dermatitis, indicating the potential for safer treatment alternatives to traditional options. The company's strategic plans to expand into additional indications and geographic markets, coupled with the potential advancement of other promising candidates like EB05 and EB07, could enhance revenue prospects and drive future growth. Collectively, these factors contribute to a strong positive outlook for Edesa Biotech's stock in the competitive biotechnology landscape.
Bears say
Edesa Biotech Inc is projected to continue experiencing negative cash flows from operating activities through FY2026, indicating ongoing financial strain. The company reported negative operating cash flows in FY2024, which raises concerns about its financial sustainability and ability to fund its product development initiatives. Given these ongoing cash flow challenges, the outlook for Edesa Biotech's financial stability remains bleak.
This aggregate rating is based on analysts' research of Edesa Biotech Inc and is not a guaranteed prediction by Public.com or investment advice.
EDSA Analyst Forecast & Price Prediction
Start investing in EDSA
Order type
Buy in
Order amount
Est. shares
0 shares